Parathyroid Gland Adenoma, Primary Hyperparathyroidism
Conditions
Brief summary
This clinical trial studies the omission of intact parathyroid hormone testing during surgery in treating patients with primary hyperparathyroidism. Omission of intact parathyroid hormone testing during parathyroid gland removal may help patients with primary hyperparathyroidism to decrease their time under anesthesia, and decrease the overall time and cost of surgery.
Detailed description
PRIMARY OBJECTIVES: I. Determine the non-inferiority of omission of parathyroid hormone (PTH) in patients who meet the biochemical and radiological criteria compared to current standard of care (i.e. use of intraoperative parathyroid hormone testing). SECONDARY OBJECTIVES: I. Cost-analysis to determine savings of omission of intraoperative PTH testing. OUTLINE: Patients undergo standard minimally invasive parathyroidectomy without PTH testing during surgery. After completion of study, patients are followed up at 2 weeks.
Interventions
OTHERLaboratory Biomarker Analysis
Correlative studies
PROCEDUREParathyroidectomy
Undergo parathyroidectomy
Sponsors
Roswell Park Cancer Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Positive 4 dimensional computed tomography (4D CT) for single gland (adenoma) primary hyperparathyroidism * Preoperative serum calcium levels \>= 10.9 mg/dL * Preoperative parathyroid hormone (PTH) elevated beyond normal range or inappropriately high for associated calcium level * Patient has no history of prior neck surgery or external radiation to neck for malignant conditions * Have an Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2 * Subject or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
Exclusion criteria
* Patient has recurrent hyperparathyroidism * 4D CT positive for multiple gland disease * Patient has inability to tolerate 4D CT scan (for example; contrast intravenous (IV) allergy, claustrophobia, renal disease) * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant or nursing female subjects; may be determined in the preoperative evaluation * Unwilling or unable to follow protocol requirements * Any condition which in the investigator's opinion deems the subject an unsuitable candidate to undergo observational study (may also include preoperative testing results including electrocardiography \[EKG\], chest x-ray, or pulmonary function tests that preclude a wide excision in the operating room)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cure of primary hyperparathyroidism following surgery with intraoperative PTH omission | At 2 weeks | Will be evaluated using a binomial exact test. If all N=60 patients achieve cure then the proposed surgery with intraoperative PTH testing committed will be considered non inferior. A 95% confidence interval about pi will be obtained. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Post-operative cost analysis | At 2 weeks | cost analysis will be based on operative time and omission of intraoperative PTH levels. |
Countries
United States
Outcome results
None listed